UK regulator calls for EU committee to assess unforeseen risks/notified body responsibilities
This article was originally published in RAJ Devices
Any discussion concerning the revision of medical device legislation in the European Union should include a careful assessment of measures that are intended to make devices safer but which may have undesirable repercussions that could threaten patient safety in an unanticipated way. This was the advice of senior UK device regulator Steve Owen when he spoke at the Medtec 2010 conference in Birmingham last month.
You may also be interested in...
The last year of the run up to the full implementation of the MDR has been characterized by a flurry of new documents and measures, but industry is adamant that medtech is heading for a crisis that will impact industry and patients alike.
With just a few months remaining until the full application of the EU Medical Device Regulation, notified body designations are still only trickling through. Ireland is the latest EU member state to have a resident MDR notified body.
In this second article of a two-part series, Eithne Lee of ISO Life Sciences global consultancy identifies some of the problems that medtech premarket innovators and SMEs are facing, with the EU MDR application date now less than four months away.